Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)

U Schmidt-Erfurth, V Chong, A Loewenstein… - British Journal of …, 2014 - bjo.bmj.com
Age-related macular degeneration (AMD) is still referred to as the leading cause of severe
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …

A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration

U Schmidt-Erfurth, SM Waldstein - Progress in Retinal and eye Research, 2016 - Elsevier
Neovascular age-related macular degeneration (AMD) has undergone substantial break-
throughs in diagnostic as well as therapeutic respect, with optical coherence tomography …

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

FG Holz, R Tadayoni, S Beatty, A Berger… - British Journal of …, 2015 - bjo.bmj.com
Background/aims Real-life anti-vascular endothelial growth factor (VEGF) therapy use in
patients with wet age-related macular degeneration (wAMD) was assessed in a …

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

N Papadopoulos, J Martin, Q Ruan, A Rafique… - Angiogenesis, 2012 - Springer
Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis
and vascular leak associated with cancers and various eye diseases. However, little …

Defining response to anti-VEGF therapies in neovascular AMD

WM Amoaku, U Chakravarthy, R Gale, M Gavin… - Eye, 2015 - nature.com
The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant
impact on the reduction of the visual loss due to neovascular age-related macular …

Age-related macular degeneration

LS Lim, P Mitchell, JM Seddon, FG Holz, TY Wong - The Lancet, 2012 - thelancet.com
Age-related macular degeneration is a major cause of blindness worldwide. With ageing
populations in many countries, more than 20% might have the disorder. Advanced age …

[HTML][HTML] Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study

R Silva, A Berta, M Larsen, W Macfadden, C Feller… - Ophthalmology, 2018 - Elsevier
Purpose To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E)
versus monthly regimens in patients with neovascular age-related macular degeneration …

Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration

RH ElSheikh, MZ Chauhan, AB Sallam - Biomolecules, 2022 - mdpi.com
Age-related macular degeneration AMD is one of the leading causes of blindness in the
elderly population. An advanced form of AMD known as neovascular AMD (nAMD) is …

[HTML][HTML] Quantitative analysis of OCT for neovascular age-related macular degeneration using deep learning

G Moraes, DJ Fu, M Wilson, H Khalid, SK Wagner… - Ophthalmology, 2021 - Elsevier
Purpose To apply a deep learning algorithm for automated, objective, and comprehensive
quantification of optical coherence tomography (OCT) scans to a large real-world dataset of …

Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of …

SJ Bakri, JE Thorne, AC Ho, JP Ehlers… - Ophthalmology, 2019 - Elsevier
Purpose To review the evidence on the safety and efficacy of anti-vascular endothelial
growth factor (VEGF) therapies for the treatment of neovascular age-related macular …